Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study

NCT ID: NCT00985608

Last Updated: 2010-01-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-30
• Study Completion Date: 2009-09-30

Brief Summary

H pylori gastric infection is one of the most prevalent infectious diseases worldwide. The discovery that most upper gastrointestinal diseases are related to H pylori infection and therefore can be treated with antibiotics is an important medical advance. Currently, a first-line triple therapy based on proton pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus two antibiotics (clarithromycin and amoxicillin or nitroimidazole) is recommended by all consensus conferences and guidelines. Even with the correct use of this drug combination, infection can not be eradicated in up to 23% of patients. Therefore, several second line therapies have been recommended. A 7 d quadruple therapy based on PPI, bismuth, tetracycline and metronidazole is the more frequently accepted. However, with second-line therapy, bacterial eradication may fail in up to 40% of cases. When H pylori eradication is strictly indicated the choice of further treatment is controversial. When available, endoscopy with culture and consequent antibiotic susceptibility testing remains the most appropriate option for patients with two eradication failures to avoid a widespread use of expensive antibiotics. The use of these drugs may also induce severe side-effects and development of H pylori resistant strains.

Resistant strains of Helicobacter pylori can display a dense biofilm with mucus and microorganisms in a coccoid shape on the mucosal surface of stomach that may have a role in determining the resistance to the antibiotic therapies. Possibly, N-acetil-cysteine (NAC) may dissolve biofilm architecture and help to eradicate resistant strains of H pylori.

Detailed Description

To evaluate the usefulness of NAC as pre-treatment attempt associated with a culture-guided antibiotic therapy as rescue therapy after multi-attempts antibiotic failure, in the first phase of the study, the effect of NAC on biofilm formation and on its demolition will be tested in vitro by adding NAC in cultured H pylori isolates from a limited number of patients (n10) with an history of at least 4 failed eradicating attempts. Two biopsy samples of gastric mucosa will be obtained during endoscopy for microbiological purpose. Specimens will be used for H pylori culture. In specimens from 5 patients, H pylori will be cultured together with NAC 2 mg, while in the other 5 cases, H pylori culture will be carried out without NAC. In these latter, after the biofilm formation, H pylori isolates will be faced with different doses of NAC (2 mg, 10 mg, and 20 mg) to observe the behavior of biofilm. In the second phase of the study, 40 patients, after at least four unsuccessful H pylori eradication attempts, will be consecutively recruited. During endoscopy, in each patient, at least 4 mucosal biopsies will be obtained from the gastric body. Two of these biopsies will be used for biofilm study at the scanning electron microscopy (SEM). The remaining biopsies will be used for H pylori culture. From culture, the in vitro antibiotic susceptibility testing together with genetic analysis of H pylori isolates will be performed. On the basis of antibiotic susceptibility testing alone, patients will then randomly assigned to receiving two different eradication schedules: Group A, patients receiving NCA 600 mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics against H pylori; group B (control), patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics. Sensitive antibiotics will be always chosen on the basis of the more favorable minimum inhibiting concentration value. all patients will have a diary to record the side effects and symptoms during therapy. Compliance will measured by counting the tablets returned after the 7-day treatment. Patients will take a control C13 urea breath test at least two months after the end of therapy. They will be also invited to repeat endoscopic examination for monitoring biofilm persistence or absence. Finally, results obtained with the two treatment arms will be compared and evaluated also on the light of genetic analyses of H pylori isolates.

Conditions

Helicobacter Pylori Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group B: antibiotic treatment (control)

patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics

Group Type: ACTIVE_COMPARATOR

Group B: antibiotic treatment (control)

Intervention Type: DRUG

patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics

Group A: NCA 600mg +antibiotics

NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics

Group Type: ACTIVE_COMPARATOR

Group A: NCA 600 mg+antibiotics

Intervention Type: DRUG

NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics

Interventions

Group A: NCA 600 mg+antibiotics

NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics

Intervention Type: DRUG

Group B: antibiotic treatment (control)

patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Both genders
• Age > 18 years
• Persistent infection from Helicobacter pylori, at gastroscopy or 13C urea breath test, after at least two antibiotic unsuccessful eradication attempts

Exclusion Criteria

• Verified allergies to the acetylcysteine or to the antibiotics to cure Helicobacter pylori
• Pregnancy, nursing

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Catholic University of the Sacred Heart

OTHER

Sponsor Role: lead

Responsible Party

Catholic University of the Sacred Heart-Institute of Internal Medicine

Principal Investigators

Giovanni Cammarota, MD

Role: PRINCIPAL_INVESTIGATOR

Catholic University, Institute of Internal Medicine

Locations

Institute of Internal Medicine - Catholic University

Rome, , Italy

Site Status: RECRUITING

Countries

Italy

Facility Contacts

Giovanni Cammarota, MD

Role: primary

gcammarota@rm.unicatt.it

0039-06-30155948

Other Identifiers

253/09

Identifier Type: -

Identifier Source: org_study_id